Drugs Xagena
Roche has announced that the European Medicines Agency ( EMA ) has validated the company’s Marketing Authorisation Application ( MAA ) of Ocrevus ( Ocrelizumab ) for the treatment of relapsing multipl ...
The U.S. Food and Drug Administration ( FDA ) has approved Ocrevus ( Ocrelizumab ) as the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis. The majority ...
European Commission ( EC ) has granted marketing authorisation for Ocrevus ( Ocrelizumab ) for patients with active relapsing forms of multiple sclerosis defined by clinical or imaging features and fo ...
